These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 21933749)

  • 1. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
    Shaw AT; Yeap BY; Solomon BJ; Riely GJ; Gainor J; Engelman JA; Shapiro GI; Costa DB; Ou SH; Butaney M; Salgia R; Maki RG; Varella-Garcia M; Doebele RC; Bang YJ; Kulig K; Selaru P; Tang Y; Wilner KD; Kwak EL; Clark JW; Iafrate AJ; Camidge DR
    Lancet Oncol; 2011 Oct; 12(11):1004-12. PubMed ID: 21933749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.
    Ou SH; Jänne PA; Bartlett CH; Tang Y; Kim DW; Otterson GA; Crinò L; Selaru P; Cohen DP; Clark JW; Riely GJ
    Ann Oncol; 2014 Feb; 25(2):415-22. PubMed ID: 24478318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.
    Zhang NN; Liu YT; Ma L; Wang L; Hao XZ; Yuan Z; Lin DM; Li D; Zhou YJ; Lin H; Han XH; Sun Y; Shi Y
    PLoS One; 2014; 9(1):e84501. PubMed ID: 24404167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH
    Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer.
    Yoshida T; Oya Y; Tanaka K; Shimizu J; Horio Y; Kuroda H; Sakao Y; Hida T; Yatabe Y
    J Clin Oncol; 2016 Oct; 34(28):3383-9. PubMed ID: 27354483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
    Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
    Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
    Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
    Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
    Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
    N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
    Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
    Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
    Zhang L; Jiang T; Li X; Wang Y; Zhao C; Zhao S; Xi L; Zhang S; Liu X; Jia Y; Yang H; Shi J; Su C; Ren S; Zhou C
    Cancer; 2017 Aug; 123(15):2927-2935. PubMed ID: 28346673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.
    Costa DB; Shaw AT; Ou SH; Solomon BJ; Riely GJ; Ahn MJ; Zhou C; Shreeve SM; Selaru P; Polli A; Schnell P; Wilner KD; Wiltshire R; Camidge DR; Crinò L
    J Clin Oncol; 2015 Jun; 33(17):1881-8. PubMed ID: 25624436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A large, single-center, real-world study of clinicopathological characteristics and treatment in advanced ALK-positive non-small-cell lung cancer.
    Chen G; Chen X; Zhang Y; Yan F; Fang W; Yang Y; Hong S; Miao S; Wu M; Huang X; Luo Y; Zhou C; Gong R; Huang Y; Zhou N; Zhao H; Zhang L
    Cancer Med; 2017 May; 6(5):953-961. PubMed ID: 28374971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.
    Kiura K; Imamura F; Kagamu H; Matsumoto S; Hida T; Nakagawa K; Satouchi M; Okamoto I; Takenoyama M; Fujisaka Y; Kurata T; Ito M; Tokushige K; Hatano B; Nishio M
    Jpn J Clin Oncol; 2018 Apr; 48(4):367-375. PubMed ID: 29474558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis.
    Johung KL; Yeh N; Desai NB; Williams TM; Lautenschlaeger T; Arvold ND; Ning MS; Attia A; Lovly CM; Goldberg S; Beal K; Yu JB; Kavanagh BD; Chiang VL; Camidge DR; Contessa JN
    J Clin Oncol; 2016 Jan; 34(2):123-9. PubMed ID: 26438117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
    Solomon BJ; Mok T; Kim DW; Wu YL; Nakagawa K; Mekhail T; Felip E; Cappuzzo F; Paolini J; Usari T; Iyer S; Reisman A; Wilner KD; Tursi J; Blackhall F;
    N Engl J Med; 2014 Dec; 371(23):2167-77. PubMed ID: 25470694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
    Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
    Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLC.
    Lei YY; Yang JJ; Zhang XC; Zhong WZ; Zhou Q; Tu HY; Tian HX; Guo WB; Yang LL; Yan HH; Chen HJ; Xie Z; Su J; Han JF; Wu YL
    Clin Lung Cancer; 2016 May; 17(3):223-31. PubMed ID: 26454342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
    Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
    Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.